65,437 trials
Arthritis, Rheumatoid
Primary: Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR) — 15.9; 34.7; 25.4; 28.2…
Depression · Substance Use
Primary: Depressive Symptoms as Measured by the Beck Depression Inventory II — 14.83; 21.82 BDI-II score
Pterygium
Primary: Number of Pterygium Hyperemia Responders at Week 16 — 6; 8 Participants
Lipoma
Primary: The Average Percent Volume Reduction in the Lipoma. — 50 Percent Volume reduction (cc^3)
Schizophrenia
Primary: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of…
Microbicide Applicator
Primary: Number of Colposcopic Findings (Baseline and After One Week of Product Use) — 3; 0; 2; 0 colposcopic findings — p=0.4870
Type 1 Diabetes Mellitus
Primary: Event Rate of "All Hypoglycemia" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)…
Schizophrenia · Schizoaffective Disorder · Central Nervous System Diseases
Primary: Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. — 0; 0; 1; 0 participants
Kidney Transplantation · Kidney Disease · Kidney Failure
Primary: Overall Participant Survival at One Year Post Kidney Transplant — 4; 5 participants
Stage 2 Diastolic Hypertension
Primary: The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6. — -8.0; -17.2; -13.3; -12.0 mm HG
Infection, Human Immunodeficiency Virus I
Primary: Plasma Amprenavir (APV) AUC (0-tau[τ]) — 22.3; NA; 24.1; NA hr*µg/mL
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
Treatment · Placebo
Primary: California Verbal Learning Test-II (CLVT-II) — 55.84; 55.39 age adjusted t-scores
Renal Transplant
Primary: Dose-Normalized Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12h) at Steady State — 51.73; 50.58 ng*hr/mL/mg — p=0.486
Procedural Sedation
Primary: Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures — 1; 1; 1; 1 particpants